Jeffrey Handwerker Talks Medicaid Pricing and Direct-to-Patient Models at MDRP Summit
Arnold & Porter Life Sciences & Healthcare Regulatory partner Jeffrey Handwerker was recently featured in NAVLIN Daily's coverage of the Informa Medicaid Drug Rebate Program Summit’s panel discussion. The article touches on a few key developments in government pricing and rebate models.
Jeffrey discussed ongoing uncertainty around Most Favored Nations pricing and related policy shifts, cautioning that “all companies, large and small, should be monitoring this” as the U.S. government considers tools ranging from tariffs to False Claims Act enforcement.
He also highlighted the potential implications of including the Maximum Fair Price in the Average Sales Price and addressed how direct-to-patient platforms may intersect with Medicaid best price rules. While sales to patients can be exempt, he emphasized that careful structuring and documentation are critical.
“If it is a direct pass-through, where the pharmacy is not getting a discount or something other than a modified service fee, that could be interpreted as a sale to patient,” Jeffrey explained.
